Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 61.06
(-0.33%)
INR 61.06
(-0.33%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 23.52 Million | -1.11 Million | -2.19 Million | 11.1 Million | 8.94 Million | 95.11 Million |
| Net Income | 7.09 Million | 7.93 Million | 10.14 Million | 19.18 Million | 14.64 Million | 5.98 Million |
| Depreciation & Amortization | 3.99 Million | 4.29 Million | 4.27 Million | 4.11 Million | 4.34 Million | 3.65 Million |
| Deferred income taxes | - | - | - | -3.54 Million | - | - |
| Stock-based compensation | - | - | - | -3.18 Million | - | - |
| Change in working capital | 10.51 Million | -10.47 Million | -13.96 Million | -6.15 Million | -8.7 Million | 84.99 Million |
| Other non-cash items | -514 Thousand | -2.86 Million | -2.65 Million | 681 Thousand | -1.34 Million | 486 Thousand |
| Investing Cash Flow | -229 Thousand | -106 Thousand | -699 Thousand | -961 Thousand | -2.06 Million | -14.12 Million |
| Investments in PPE | -229 Thousand | -106 Thousand | -699 Thousand | -5.66 Million | -2.06 Million | -14.12 Million |
| Acquisitions | - | - | - | 4.7 Million | 2.06 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | 4.7 Million | -2.06 Million | - |
| Financing Cash Flow | -834 Thousand | 151 Thousand | -58 Thousand | -8.3 Million | -5.67 Million | -816 Thousand |
| Debt repayment | -834 Thousand | -576 Thousand | -348 Thousand | -7.62 Million | -4.45 Million | -787 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -415 Thousand | 727 Thousand | 290 Thousand | -681 Thousand | -1.22 Million | -29 Thousand |
| Accounts receivables | -125.26 Million | -133.29 Million | 100.44 Million | 124.9 Million | -176.83 Million | 9.55 Million |
| Accounts payables | 149.05 Million | 120.53 Million | -152.55 Million | -100.65 Million | 173.34 Million | -5.58 Million |
| Inventory | -13.36 Million | 797 Thousand | 30.51 Million | -26.52 Million | -5.01 Million | -1.66 Million |
| Other working capital | 92 Thousand | 1.48 Million | 7.63 Million | -3.87 Million | -193 Thousand | 82.67 Million |
| Cash at beginning of period | 377 Thousand | 1.44 Million | 4.4 Million | 2.56 Million | 1.36 Million | 3.74 Million |
| Cash at end of period | 22.83 Million | 376 Thousand | 1.44 Million | 4.4 Million | 2.56 Million | 1.36 Million |
| Capital Expenditure | -229 Thousand | -106 Thousand | -699 Thousand | -5.66 Million | -2.06 Million | -14.12 Million |
| Effect of forex changes on cash | - | - | -1000.00 | - | -1000.00 | -82.55 Million |
| Net cash flow / Change in cash | 22.45 Million | -1.07 Million | -2.95 Million | 1.84 Million | 1.19 Million | -2.38 Million |
| Free Cash Flow | 23.29 Million | -1.22 Million | -2.89 Million | 5.44 Million | 6.87 Million | 80.98 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 7.09 Million | 2.48 Million | 933 Thousand | 1.22 Million | 2.44 Million | 7.93 Million |
| Depreciation & Amortization | 3.99 Million | - | 1.07 Million | 1.07 Million | 1.07 Million | 4.29 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 10.51 Million | - | - | - | - | -10.47 Million |
| Other non-cash items | -514 Thousand | -2.48 Million | -933 Thousand | -1.22 Million | -2.44 Million | -2.86 Million |
| Investing Cash Flow | -229 Thousand | - | - | - | - | -106 Thousand |
| Investments in PPE | -229 Thousand | - | - | - | - | -106 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -834 Thousand | - | - | - | - | 151 Thousand |
| Debt repayment | -834 Thousand | - | - | - | - | -576 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -415 Thousand | - | - | - | - | 727 Thousand |
| Accounts receivables | -125.26 Million | - | - | - | - | -133.29 Million |
| Accounts payables | 149.05 Million | - | - | - | - | 120.53 Million |
| Inventory | -13.36 Million | - | - | - | - | 797 Thousand |
| Other working capital | 92 Thousand | - | - | - | - | 1.48 Million |
| Cash at beginning of period | 377 Thousand | - | 575 Thousand | -654 Thousand | 377 Thousand | 1.44 Million |
| Cash at end of period | 22.83 Million | - | 933 Thousand | 575 Thousand | 2.44 Million | 376 Thousand |
| Capital Expenditure | -229 Thousand | - | - | - | - | -106 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 22.45 Million | - | 358 Thousand | 1.22 Million | 2.06 Million | -1.07 Million |
| Free Cash Flow | 23.29 Million | - | 933 Thousand | 1.22 Million | 2.44 Million | -1.22 Million |
CROISSANCE
MSIU
BDR
TWRKF
BGIP3
PARAGMILK